Ondine Biomedical Appoints Interim CFO
Why we think this is neutral
The RNS announcement is about the appointment of a new interim CFO, which is a routine operational update and does not contain any significant financial or strategic news that would impact the company's performance or outlook.
Key Points
- Appointment of Alan Thomas as non-Board interim Chief Financial Officer (CFO)
- Mr. Thomas has over 25 years of leadership experience in the healthcare, biotechnology, and infrastructure sectors
- He will support Ondine's next phase of growth and the continued expansion of its light-activated antimicrobial technology
Summary
The healthcare company has appointed a new interim Chief Financial Officer to support its growth plans.
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, has appointed Alan Thomas as non-Board interim Chief Financial Officer (CFO) of the Company, effective immediately. Mr. Thomas succeeds Michael Behlke, who is stepping down from his role as CFO and COO for personal reasons.
GENERAL UPDATE